NPS delays BLA submission for hypoparathyroidism therapy

NPS Pharmaceuticals Inc. (NASDAQ:NPSP) delayed its planned submission of a BLA to FDA for hypoparathyroidism product Natpara to mid-2013. The company had planned to submit it by year end. NPS said it ...